Lisa Anson, chief executive of (), tells Proactive London's Andrew Scott they've received the regulatory green light to re-commence its phase I/II clinical trial of RXC004 on people with solid tumours.
It means the company is on track to restart the study as planned in the first-half.
RXC004 is a new breed of cancer drug called a porcupine inhibitor, with this particular formulation targeting the Wnt signalling pathway, which known to be heavily involved in cell growth and division.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE
